Ilusat Võidupüha ja jaanilaupäeva kõigile foorumlastele!<br/><br/>Nii nagu ikka, USA turud on täna avatud tavapärasel ajal ning hetkel on USA futuurid kauplemas kerges plussis.<br/><br/><b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>SGH +2.1%, SNX +0.5%<br/><b>Select financial names showing strength following stress tests:</b><br/>DFS +2.4%, RF +1.5%, BAC +0.9%, WFC +0.8%, C +0.7%, JPM +0.6%, GS +0.6%, . <br/><b>Other news:</b><br/>AVEO +60.3% (Eusa Pharma received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending marketing authorisation of FOTIVDA (tivozanib))<br/>SNCR +34.6% (Siris Capital Group affirms 12.93% active stake, delivers letter indicating that they believe they could be in a position to acquire the Company in an all-cash acquisition at $18.00/share)<br/>CARA +10.3% (FDA has granted Breakthrough Therapy designation to I.V. CR845)<br/>BDSI +7% (announces that Health Canada has issued a Notice of Compliance approving BELBUCA)<br/>IDRA +6.9% ( confirmed the FDA granted orphan drug designation for IMO-2125, an agonist of endosomal Toll-like receptor 9 for the treatment of melanoma Stages IIb to IV)<br/>JONE +3.3% ( to sell several non-core assets for up to $70 million; continues to actively market additional non-core assets)<br/>ADHD +2.7% (conducting a process to explore and review a range of strategic alternatives)<br/>CNAT +2% (granted orphan designation by the FDA for its compound for the treatment of primary sclerosing cholangitis)<br/>THC +1.9% (continued strength)<br/>HIMX +1.8% (increases annual dividend per ADS to $0.24/ADS from $0.12/ADS)<br/>RIGL +1.4% (Rigel Pharma will present data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE in patients with chronic or persistent immune thrombocytopenia on June 24 from 12:30 - 12:45pm (CEST) at the European Hematology Association 22nd Annual Congress)<br/>EVH +1.4% (prices secondary offering by selling shareholders of 4.5 mln shares of common stock at $25.90 per share)<br/>PFE +1.3% (receives Complete Response Letter from the FDA regarding the Biologics License Application for its proposed epoetin alfa biosimilar)<br/><b>Analyst comments:</b><br/>CBAY +4.1% (initiated with a Outperform at Oppenheimer)<br/>AKS +4.1% (upgraded to Buy from Hold at Deutsche Bank)<br/>X +2.9% (upgraded to Buy from Hold at Deutsche Bank)<br/>DBVT +2.7% (initiated with a Buy at Deutsche Bank)<br/>RH +2.2% (upgraded to Buy from Hold at Deutsche Bank )<br/>VRTX +1.3% (upgraded to Buy from Hold at Needham)<br/>GILD +1% (initiated with a Buy at Deutsche Bank)<br/>BIIB +0.9% (initiated with a Buy at Deutsche Bank)<br/>OCLR +0.8% (initiated with a Buy at DA Davidson)<br/>SBUX +0.6% (initiated with a Overweight last night after the close at KeyBanc Capital Mkts)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>BBBY -10.5%, AMSWA -7.3%, BBRY -4.2%, SONC -2.4%, FINL -2.4%<br/>Other news:<br/>OCUL -11.6% (names Antony Mattessich to succeed Dr. Amar Sawhney as CEO on or before September 30 )<br/>WKHS -8.9% (entered into at the market issuance sales agreement with Cowen to offer common stock having an aggregate offering price of up to $25,000,000)<br/>BLUE -5.8% (presents interim data from the ongoing Northstar-2 (HGB-207) Phase 3 clinical study of LentiGlobin)<br/>CLSN -4.2% (following late surge higher after canceling its registered direct offering of common stock announced Monday, June 19)<br/>PIR -2.5% (BBBY sympathy)<br/>WSM -1% (BBBY sympathy)<br/><b>Analyst comments:</b><br/>HAIN -3% (downgraded to Neutral from Overweight at JP Morgan)<br/>LEJU -2% (downgraded to Underweight from Neutral at JP Morgan)<br/>USG -1.5% (initiated with a Underperform at Credit Suisse)<br/>SKT -1.4% (downgraded to Underperform from Neutral at BofA/Merrill)<br/>MELI -1.2% (downgraded to Neutral from Buy at Citigroup)<br/>CAT -1.1% (downgraded to Hold from Buy at Deutsche Bank)<br/><br/>Briefing.com